Immunocore Holdings Plc (IMCR) Hits 52-Week Low Despite 34% Surge in KIMMTRAK Sales
巴克莱银行维持Immunocore(IMCR.US)买入评级,维持目标价66美元
Barclays analyst Peter Lawson maintains $Immunocore(IMCR.US)$ with a buy rating, and maintains the target price at $66.According to TipRanks data, the analyst has a success rate of 43.2% and a total
Barclays Gives a Buy Rating to Immunocore Holdings (IMCR)
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
A Quick Look at Today's Ratings for Immunocore(IMCR.US), With a Forecast Between $78 to $100
On Sep 17, major Wall Street analysts update their ratings for $Immunocore(IMCR.US)$, with price targets ranging from $78 to $100.TD Cowen analyst Tyler Van Buren maintains with a buy rating, and
Immunocore Holdings Is Maintained at Buy by Needham
Immunocore Hldgs Analyst Ratings
Express News | Immunocore : Needham Cuts Target Price to $78 From $81
TD Cowen Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $90
TD Cowen analyst Tyler Van Buren maintains $Immunocore(IMCR.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success rate of 47.7% and a
Capital One Financial Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $90
Capital One Financial analyst Naureen Quibria maintains $Immunocore(IMCR.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success rate of 24.
Immunocore Presents Phase 1 Data of Brenetafusp, an ImmTAC Bispecific Targeting PRAME, in Patients With Ovarian Cancer
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt In A Risky Way?
Immunocore to Present at the 2024 Cantor Global Healthcare Conference
Mizuho Securities Maintains Immunocore(IMCR.US) With Buy Rating, Announces Target Price $72
Mizuho Securities analyst Graig Suvannavejh maintains $Immunocore(IMCR.US)$ with a buy rating, and sets the target price at $72.According to TipRanks data, the analyst has a success rate of 43.5%
Buy Rating Affirmed for Immunocore Holdings on Promising Brenetafusp Prospects and Strong Company Fundamentals
Barclays Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $66
Barclays analyst Peter Lawson maintains $Immunocore(IMCR.US)$ with a buy rating, and maintains the target price at $66.According to TipRanks data, the analyst has a success rate of 41.7% and a total
Immunocore Holdings (IMCR) Receives a Buy From Barclays
Immunocore CFO to Leave Company
Immunocore Holdings: Di Donato Has Accepted New CEO at a Private, Early-Stage Biotech >IMCR
Express News | Immunocore Holdings PLC - CFO Brian Di Donato to Leave End of Year